HDAC6 and DNMT inhibition affect immunogenicity of ovarian cancer cells: A rationale for combining epigenetic and immune therapy in ovarian cancer

被引：1
|
作者：
Srivastava, Aneil P. [1 ]
Moufarrij, Sara M. [1 ]
Hadley, Melissa [1 ]
Chisholm, Sarah [1 ]
Lopez-Acevedo, Micael [1 ]
Villagra, Alejandro [1 ]
Chiappinelli, Katherine B. [1 ]
机构：
[1] George Washington Univ, Washington, DC USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1395
引用
收藏
页数：2
相关论文
共 50 条
  • [41] HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape
    Zamperla, Michela Gottardi
    Illi, Barbara
    Barbi, Veronica
    Cencioni, Chiara
    Santoni, Daniele
    Gagliardi, Stella
    Garofalo, Maria
    Zingale, Gabriele Antonio
    Pandino, Irene
    Sbardella, Diego
    Cipolla, Lina
    Sabbioneda, Simone
    Farsetti, Antonella
    Ripamonti, Chiara
    Fossati, Gianluca
    Steinkuhler, Christian
    Gaetano, Carlo
    Atlante, Sandra
    CLINICAL EPIGENETICS, 2024, 16 (01)
  • [42] Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
    Lee, Elizabeth K.
    Konstantinopoulos, Panagiotis A.
    TRENDS IN CANCER, 2019, 5 (09): : 524 - 528
  • [43] MicroRNA-mediated epigenetic regulation of HDAC8 and HDAC6: Functional significance in cervical cancer
    Naik, Debasmita
    Kalle, Arunasree M.
    NON-CODING RNA RESEARCH, 2024, 9 (03): : 732 - 743
  • [44] Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells
    Kamemura, Kazuo
    Ito, Akihiro
    Shimazu, Tadahiro
    Matsuyama, Akihisa
    Maeda, Satoko
    Yao, Tso-Pang
    Horinouchi, Sueharu
    Khochbin, Saadi
    Yoshida, Minoru
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 374 (01) : 84 - 89
  • [45] HDAC6 IS A NOVEL REGULATOR OF MTOR ACTIVITY IN COLORECTAL CANCER CELLS
    Zhou, Yuning
    Wang, Qingding
    Weiss, Heidi L.
    Evers, B. Mark
    GASTROENTEROLOGY, 2018, 154 (06) : S874 - S874
  • [46] Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease Ovarian Cancer Chemoresistance
    Cacan, Ercan
    Ali, Mourad W.
    Boyd, Nathaniel H.
    Hooks, Shelley B.
    Greer, Susanna F.
    PLOS ONE, 2014, 9 (01):
  • [47] Ovarian cancer stem cells (OCSCs): Therapy for advanced chemoresistant ovarian cancer.
    Sengupta, Prattusha
    Gangopadhyay, Sudeshna
    Sengupta, Saubhik
    Ray, Ujjal Kanti
    Mukhopadhyay, Ashis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] CDK4/6 inhibition as maintenance therapy in ovarian cancer.
    Iyengar, Mangala
    Coffman, Lan
    Buckanovich, Ronald
    CLINICAL CANCER RESEARCH, 2016, 22
  • [49] Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment
    Catalano, Martina
    Francesco Iannone, Luigi
    Cosso, Federica
    Generali, Daniele
    Mini, Enrico
    Roviello, Giandomenico
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (11) : 923 - 936
  • [50] HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells
    Yoo, Jung
    Jeon, Yu Hyun
    Lee, Dong Hoon
    Kim, Go Woon
    Lee, Sang Wu
    Kim, So Yeon
    Park, Jongsun
    Kwon, So Hee
    ONCOLOGY LETTERS, 2021, 21 (03)
12345